1. ALLA AKTIER
  2. NYHETER
  3. PROLIGHT DIAGNOSTICS

Prolight Diagnostics

Nyheter Prolight Diagnostics Nyheter alla bolag

Emergers publishes updated analysis for Prolight Diagnostics

Emergers has updated its analysis of Prolight Diagnostics, noting among other things that the investment case has strengthened due to the fully subscribed rights issue and strong international interest following the presentation of the fully operational commercial prototype at the international ADLM congress in the US.
 
Read the article here: https://www.emergers.se/prolight-m25/

For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Emergers publishes updated analysis for Prolight Diagnostics

Datum 2025-08-29, kl 13:40
Källa MFN
Bifogade filer
Emergers publishes updated analysis for Prolight Diagnostics
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!